Safety Reading Notes

Read safety context beside the research guide.

The CBN and sleep pilot source set includes safety-context rows around Adverse events. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 39612156

Evidence class: preliminary human

PubMed For Dummies Article

CBN and sleep pilot Evidence Review: the long-form source walk-through

Quick read
  • CBN and sleep pilot currently has 23 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39612156
  • The evidence classes most visible in the row language are preliminary human (15), insufficient (4), preclinical (3), and mechanistic or pharmacological (1). PMID 34468204
  • The study-design language most visible in the row language is double-blind randomized placebo-controlled study (6), randomized double-blind placebo-controlled crossover trial (5), rat polysomnography study (3), and other mapped categories (8). PMID 37796540
  • The repeated topics are Sleep (5), Overall sleep disturbance (2), Wake after sleep onset (2), Sleep onset latency (2), and other mapped categories (12), which tells the reader where to start opening PubMed and DOI links. PMID 39204082

Start with the research question

CBN and sleep pilot is built from 23 source-backed evidence row(s) and 10 research source(s). The current evidence classes read as preliminary human (15), insufficient (4), preclinical (3), and mechanistic or pharmacological (1), and the study-design language most often reads as double-blind randomized placebo-controlled study (6), randomized double-blind placebo-controlled crossover trial (5), rat polysomnography study (3), and other mapped categories (8). PMID 39612156

The row-level question is not simply whether CBN and sleep pilot is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Sleep (5), Overall sleep disturbance (2), Wake after sleep onset (2), Sleep onset latency (2), and other mapped categories (12). PMID 39204082

Human evidence 13 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 41698831

Preclinical evidence 3 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39528623

Mechanistic evidence 1 row

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 37612115

Limits and uncertainty 6 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 35537535

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 42207928

Where this page has the most source density

The largest bucket surfaced for this page is Sleep: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Overall sleep disturbance, which gives readers another way to see what the literature repeatedly circles. PMID 39612156

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 39204082

Bucket chapters: what the literature is circling

Sleep: insufficient

3 research sources 3 rows (19, 20, 21) Evidence class: insufficient

This bucket summarizes source-backed rows focused on Sleep: insufficient. It currently draws from 3 research source(s), so the exact study type matters. PMID 39612156

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39612156

  • Evidence row 3

    CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind rand... PMID 37796540

  • Evidence row 19

    CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 39612156

  • Evidence row 20

    CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 37612115

Overall sleep disturbance

2 research sources 2 rows (4, 14) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Overall sleep disturbance. It currently draws from 2 research source(s), so the exact study type matters. PMID 39204082

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 39204082

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 4

    CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose... PMID 39204082

  • Evidence row 14

    CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN;... PMID 37796540

Sleep onset latency

2 research sources 2 rows (7, 16) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Sleep onset latency. It currently draws from 2 research source(s), so the exact study type matters. PMID 41698831

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41698831

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 7

    CBN decreases Sleep onset latency; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 30... PMID 41698831

  • Evidence row 16

    CBN no detected effect on Sleep onset latency; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg... PMID 37796540

Sleep: preliminary human

2 research sources 2 rows (107, 108) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Sleep: preliminary human. It currently draws from 2 research source(s), so the exact study type matters. PMID 42207928

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 42207928

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 107

    CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes). PMID 42207928

  • Evidence row 108

    CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 39980821

Wake after sleep onset

2 research sources 2 rows (6, 17) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Wake after sleep onset. It currently draws from 2 research source(s), so the exact study type matters. PMID 41698831

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41698831

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

  • Evidence row 6

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover... PMID 41698831

  • Evidence row 17

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20... PMID 37796540

Adverse events

1 research source 15 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Adverse events. It currently draws from 1 research source(s), so the exact study type matters. PMID 41698831

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 41698831

  • Evidence row 15

    CBN associated with Adverse events; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: s... PMID 41698831

Daytime fatigue

1 research source 18 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Daytime fatigue. It currently draws from 1 research source(s), so the exact study type matters. PMID 37796540

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 37796540

  • Evidence row 18

    CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN... PMID 37796540

Nighttime awakenings

1 research source 2 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Nighttime awakenings. It currently draws from 1 research source(s), so the exact study type matters. PMID 37796540

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 37796540

  • Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; durat... PMID 37796540

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (13 row(s)), mechanistic evidence (1 row(s)), and safety/tolerability context (2 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39612156

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 39204082

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 39980821
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 39612156
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 34468204

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39612156

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 39204082

Source-reading checklist for CBN and sleep pilot

  1. Open the linked PubMed or DOI record. PMID 37796540
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39204082
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 41698831
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 39528623
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 37612115

Source Notes

CBN and sleep pilot source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1

    CBN associated with sleep-promoting claims in the pre-2021 evidence base; evidence class: insufficient (study design: narrative review). PMID 34468204

    Evidence class: insufficient; Study design: narrative review. Source: Cannabinol and Sleep: Separating Fact from Fiction
  2. Evidence row 2

    CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  3. Evidence row 3

    CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  4. Evidence row 4

    CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: PROMIS Sleep Disturbance 8A). PMID 39204082

    Evidence class: preliminary human; Study design: decentralized randomized double-blind placebo-controlled trial. Source: A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep
  5. Evidence row 5

    CBN no detected effect on Side effect frequency; evidence class: preliminary human (population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: Side effect frequency). PMID 39204082

    Evidence class: preliminary human; Study design: decentralized randomized double-blind placebo-controlled trial. Source: A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep
  6. Evidence row 6

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  7. Evidence row 7

    CBN decreases Sleep onset latency; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  8. Evidence row 8

    CBN increases Subjective sleep quality; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  9. Evidence row 9

    CBN increases NREM-2 sleep; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: polysomnography NREM-2 sleep). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  10. Evidence row 10

    CBN increases Total sleep time; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time). PMID 39528623

    Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
  11. Evidence row 11

    CBN increases NREM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep). PMID 39528623

    Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
  12. Evidence row 12

    CBN increases REM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep). PMID 39528623

    Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
  13. Evidence row 13

    CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological (population or model: rats; study design: rat and pharmacological study). PMID 39528623

    Evidence class: mechanistic or pharmacological; Study design: rat and pharmacological study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
  14. Evidence row 14

    CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  15. Evidence row 15

    CBN associated with Adverse events; evidence class: preliminary human (population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN, or placebo; outcome measure: mild-to-moderate adverse events across arms). PMID 41698831

    Evidence class: preliminary human; Study design: randomized double-blind placebo-controlled crossover trial. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  16. Evidence row 16

    CBN no detected effect on Sleep onset latency; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  17. Evidence row 17

    CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  18. Evidence row 18

    CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue). PMID 37796540

    Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
  19. Evidence row 19

    CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 39612156

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Using Cannabis and CBD to Sleep: An Updated Review.
  20. Evidence row 20

    CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 37612115

    Evidence class: insufficient; Study design: Human clinical study. Source: Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.
  21. Evidence row 21

    CBN studied for Sleep; evidence class: insufficient (study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 35537535

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids, Insomnia, and Other Sleep Disorders.
  22. Evidence row 107

    CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes). PMID 42207928

    Evidence class: preliminary human. Source: Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis.
  23. Evidence row 108

    CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 39980821

    Evidence class: preliminary human; Study design: Human clinical study. Source: Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.